Abstract
In March 2022, we observed samples with a negative fluorescent signal (60.5%, n = 43) for the influenza A matrix gene and a stronger positive signal for subtype A(H3N2). Forty‐three samples were positive in InfA (H3N2) (mean Cq 30.9, range 23.9–35.1), and 26 of the 43 samples were negative in InfA matrix (mean Cq 28.0, range 23.2–30.6). Our multiplex test is a laboratory‐developed four‐target, four‐color influenza A reverse‐transcription PCR assay targeting the matrix gene, subtypes A(H3N2) and A(H1N1)pdm09. Several samples were negative when retested on commercial influenza Point‐of‐Care assays. As the matrix gene is a stand‐alone target in most commercial diagnostic assays, we caution against false‐negative subtype A test results.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.